Rapidly progressive fatal interstitial lung disease in a patient with systemic sclerosis
- PMID: 19337287
- DOI: 10.1038/nrrheum.2009.30
Rapidly progressive fatal interstitial lung disease in a patient with systemic sclerosis
Abstract
Background: A 36-year-old woman developed new-onset Raynaud phenomenon and rapidly progressive dyspnea over a 2-week period. A lung biopsy demonstrated pauci-inflammatory nonspecific pneumonitis, which proved refractory to systemic corticosteroid and intravenous cyclophosphamide therapy. Her preterminal course in an intensive care unit was typified by sequential organ failure. Postmortem examination showed extensive organ fibrosis, including severe diffuse alveolar damage and parenchymal fibrosis, and a notable lack of potentially treatable tissue inflammation.
Investigations: Chest radiography, physical examination, screening for autoantibodies, measurement of serum creatinine, creatine phosphokinase, and brain natriuretic peptide levels, cardiac examination, pulmonary function tests, electrocardiography, transthoracic Doppler echocardiography, right heart catheterization, high-resolution thoracic CT, pulmonary ventilation/perfusion scan, lung biopsy.
Diagnosis: Interstitial lung disease associated with diffuse systemic sclerosis.
Management: Treatment with oxygen, oral and intravenous corticosteroids, mycophenolate mofetil and intravenous cyclophosphamide.
Similar articles
-
[Interstitial lung disease in systemic sclerosis].Presse Med. 2006 Dec;35(12 Pt 2):1943-51. doi: 10.1016/s0755-4982(06)74929-6. Presse Med. 2006. PMID: 17159721 Review. French.
-
Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease.Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S142-7. Epub 2015 Sep 1. Clin Exp Rheumatol. 2015. PMID: 26339893
-
Expert Perspectives On Clinical Challenges: Expert Perspectives: Challenges in Scleroderma.Arthritis Rheumatol. 2020 Sep;72(9):1415-1426. doi: 10.1002/art.41406. Epub 2020 Aug 9. Arthritis Rheumatol. 2020. PMID: 32562363 Review.
-
Systemic sclerosis-associated interstitial lung disease.Lancet Respir Med. 2020 Mar;8(3):304-320. doi: 10.1016/S2213-2600(19)30480-1. Epub 2020 Feb 27. Lancet Respir Med. 2020. PMID: 32113575 Review.
-
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25. Lancet Respir Med. 2016. PMID: 27469583 Free PMC article. Clinical Trial.
Cited by
-
Multidisciplinary approach to anti-MDA5 antibody-positive dermatomyositis associated with rapidly progressive interstitial lung disease.BMJ Case Rep. 2022 Mar 2;15(3):e246192. doi: 10.1136/bcr-2021-246192. BMJ Case Rep. 2022. PMID: 35236677 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical